Medicines | Representational image | Pexels
Medicines | Representational image | Pexels
Text Size:

Tokya: India’s government banned exports of hydroxychloroquine, as global demand surges for the malaria drug touted by U.S. President Donald Trump as a potential coronavirus treatment.

Exports will be limited to fulfilling existing contracts, while certain shipments on humanitarian grounds may also be allowed on a case-by-case basis, according to a statement issued Wednesday by the Directorate General of Foreign Trade.

Trump has vowed to make the medication widely available to fight the pandemic, calling the drug a “game changer” in the treatment of the coronavirus.

Though there is no conclusive scientific evidence that hydroxychloroquine can treat the infection from the novel pathogen, U.S. hospitals and consumers have begun stockpiling the drug after reports of its efficacy in some small clinical studies — but not in others — began circulating online and in the media. In India, the government is recommending health-care workers take the drug regularly as a preventive measure to avoid contracting the infection while treating Covid-19 patients.

Cadila Healthcare Ltd., the world’s largest maker of an anti-malarial drug, has said it plans to boost capacity more than ten-fold to meet the surging global demand. Sharvil Patel, the Ahmedabad-based company’s managing director, said the company will increase production of hydroxychloroquine sulphate to as much as 35 tons, or about 200 million individual doses per month, from about 3 tons per month currently.

The rush to make this cheap and decades-old medicine easily accessible led the U.S. Food & Drug Administration to lift import restrictions on three plants of another Indian pharmaceutical company, Ipca Laboratories Ltd., on March 20.-Bloomberg


Also read: How do you test for coronavirus? All you want to know about testing kits, process, results


 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And have just turned three.

At ThePrint, we invest in quality journalists. We pay them fairly. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous and questioning journalism. Please click on the link below. Your support will define ThePrint’s future.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here